{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:01:17Z","timestamp":1787968877655,"version":"build-2784847793"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40265-025-02165-1","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T22:05:42Z","timestamp":1744841142000},"page":"839-843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Crinecerfont: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"1","key":"2165_CR1","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-21-0794","volume":"186","author":"A Prete","year":"2021","unstructured":"Prete A, Auchus RJ, Ross RJ. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021;186(1):R1\u201314.","journal-title":"Eur J Endocrinol"},{"key":"2165_CR2","unstructured":"US Food & Drug Administration. FDA Approves New Treatment for Congenital Adrenal Hyperplasia [media release]. 13 Dec 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-congenital-adrenal-hyperplasia."},{"key":"2165_CR3","unstructured":"Neurocrine Biosciences. CRENESSITY\u2122 (Crinecerfont) capsules, for oral use: US prescribing information. 2024. https:\/\/pi.neurocrine.com\/crenessity\/CRENESSITY-Full-US-Prescribing-Information.pdf. Accessed 16 Dec 2024."},{"key":"2165_CR4","unstructured":"Neurocrine Biosciences. 2023 annual report. 2023. https:\/\/www.neurocrine.com\/media\/documents\/2023Annual-Report_3vK5hGJ.pdf. Accessed 17 Jan 2025."},{"issue":"11","key":"2165_CR5","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1210\/clinem\/dgad270","volume":"108","author":"RS Newfield","year":"2023","unstructured":"Newfield RS, Sarafoglou K, Fechner PY, et al. Crinecerfont, a CRF1 receptor antagonist, lowers adrenal androgens in adolescents with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2023;108(11):2871\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2165_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1210\/clinem\/dgab749","volume":"107","author":"RJ Auchus","year":"2022","unstructured":"Auchus RJ, Sarafoglou K, Fechner PY, et al. Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2022;107(3):801\u201312.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2165_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2404655","volume":"391","author":"K Sarafoglou","year":"2024","unstructured":"Sarafoglou K, Kim MS, Lodish M, et al. Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia. N Engl J Med. 2024;391(6):493\u2013503.","journal-title":"N Engl J Med"},{"issue":"6","key":"2165_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2404656","volume":"391","author":"RJ Auchus","year":"2024","unstructured":"Auchus RJ, Hamidi O, Pivonello R, et al. Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia. N Engl J Med. 2024;391(6):504\u201314.","journal-title":"N Engl J Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02165-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02165-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02165-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:02:22Z","timestamp":1747998142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02165-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2165"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02165-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"10 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}